文献速递心力衰竭与心肌病

氧化三甲胺:心力衰竭治疗的潜在靶点

Trimethylamine oxide: a potential target for heart failure therapy.
PubMed 文献 · Heart · 2022-05-25

心力衰竭是心血管疾病晚期的临床综合征,具有高患病率、高死亡率和高再住院率。肠道微生态研究为揭示疾病发生和药物作用机制提供了新方向,膳食中的胆碱和左卡尼汀经肠道微生物代谢为三甲胺,再经肝脏FMO3氧化为氧化三甲胺(TMAO)。循环TMAO水平与心衰不良结局(死亡和再入院)相关,TMAO水平较低提示预后较好;随着心衰进展,患者TMAO浓度逐渐升高。基于心衰肠道假说,探索靶向肠道菌群代谢物TMAO的治疗策略可能更新心衰治疗理念并提高疗效。

要点

  • 循环TMAO水平与心衰不良结局(死亡和再入院)相关,较低TMAO水平提示预后较好。
  • 随着心衰进展,患者TMAO浓度逐渐升高。
  • 靶向肠道菌群或相关酶以降低循环TMAO水平,可能影响心衰患者预后,已成为研究热点。

核心结论

  • 基于心衰肠道假说,探索靶向肠道菌群代谢物TMAO的治疗策略可能更新心衰治疗理念并提高疗效。

研究设计与样本

  • 本文为综述,围绕心衰肠道假说与肠道微生态研究,汇总TMAO代谢途径及其与心衰预后关系的证据。

主要发现

  • 膳食中的胆碱和左卡尼汀经肠道微生物代谢为三甲胺(TMA),TMA吸收入血后经门静脉循环进入肝脏,由含黄素单加氧酶(FMO)家族尤其是FMO3氧化为氧化三甲胺(TMAO)。
  • 循环TMAO水平与心衰不良结局(死亡和再入院)相关,TMAO水平较低提示预后较好。
  • 随着心衰进展,患者TMAO浓度逐渐升高。

临床怎么用

  • 可将循环TMAO水平作为心衰预后评估的参考指标,较低水平提示预后较好。
  • 干预肠道菌群或相关酶以降低循环TMAO水平,可能成为改善心衰预后的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) is a clinical syndrome in the late stage of cardiovascular disease and is associated with high prevalence, mortality and rehospitalisation rate. The pathophysiological mechanisms of HF have experienced the initial 'water-sodium retention' mode to 'abnormal hemodynamics' mode, and subsequent to 'abnormal activation of neuroendocrine' mode, which has extensively promoted the reform of HF treatment and updated the treatment concept. Since the Human Microbiome Project commencement, the study on intestinal microecology has swiftly developed, providing a new direction to reveal the occurrence of diseases and the mechanisms behind drug effects. Intestinal microecology comprises the gastrointestinal lumen, epithelial secretion, food entering the intestine, intestinal flora and metabolites. Choline and L-carnitine in the diet are metabolised to trimethylamine (TMA) by the intestinal micro-organisms, with TMA being absorbed into the blood. TMA then enters the liver through the portal vein circulation and is oxidised to trimethylamine oxide (TMAO) by the hepatic flavin-containing mono-oxygenase (FMO) family, especially FMO3. The circulating TMAO levels are associated with adverse outcomes in HF (mortality and readmission), and lower TMAO levels indicate better prognosis. As HF progresses, the concentration of TMAO in patients gradually increases. Whether the circulating TMAO level can be decreased by intervening with the intestinal microflora or relevant enzymes, thereby affecting the prognosis of patients with HF, has become a research hotspot. Therefore, based on the HF intestinal hypothesis, exploring the treatment strategy for HF targeting the TMAO metabolite of the intestinal flora may update the treatment concept in HF and improve its therapeutic effect.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Lv S, Wang Y, Zhang W, et al. Trimethylamine oxide: a potential target for heart failure therapy. Heart. 2022. PMID: 34611047. doi:10.1136/heartjnl-2021-320054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。